Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Immunobiology. 2012 Nov;217(11):1097-105. doi: 10.1016/j.imbio.2012.07.012.
Hemodialysis is the most common method used to remove waste and hazardous products of metabolism in patients suffering from renal failure. Hundreds of thousands of people with end-stage renal disease undergo hemodialysis treatment in the United States each year. Strikingly, the 5-year survival rate for all dialysis patients is only 35%. Most of the patients succumb to cardiovascular disease that is exacerbated by the chronic induction of inflammation caused by contact of the blood with the dialysis membrane. The complement system, a strong mediator of pro-inflammatory networks, is a key contributor to such biomaterial-induced inflammation. Though only evaluated in experimental ex vivo settings, specific targeting of complement activation during hemodialysis has uncovered valuable information that points toward the therapeutic use of complement inhibitors as a means to control the unwelcomed inflammatory responses and consequent pathologies in hemodialysis patients.
血液透析是肾衰竭患者用于清除代谢废物和有害物质的最常用方法。美国每年都有数十万名终末期肾病患者接受血液透析治疗。令人惊讶的是，所有透析患者的 5 年生存率仅为 35%。大多数患者死于心血管疾病，这种疾病因血液与透析膜接触导致的慢性炎症诱导而加剧。补体系统是促炎网络的主要介质，是导致这种生物材料诱导炎症的关键因素。尽管仅在实验性离体环境中进行了评估，但在血液透析过程中对补体激活的特异性靶向已揭示了有价值的信息，表明使用补体抑制剂作为控制血液透析患者不受欢迎的炎症反应和随后病理的治疗手段具有一定的可行性。
